At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prevention of Cisplatin Ototoxicity With the Antioxidant Alpha-Lipoic Acid
In Brief
A Phase 3 clinical trial evaluating alpha-lipoic acid, Audiology, and 2 other interventions for Ototoxicity and Unspecified Adult Solid Tumor. Completed, enrolled 39 participants across 2 sites.
Detailed Summary
RATIONALE: Alpha-lipoic acid may prevent or lessen hearing loss caused by cisplatin. PURPOSE: This randomized clinical trial is studying the effectiveness of alpha-lipoic acid in preventing hearing loss in cancer patients undergoing treatment with cisplatin.
Study Details
Timeline
Interventions
Supplements (1200mg once a day) or placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
otoscopy, immittance screening, noise exposure questionnaire and individualized behavioral pure-tone in the convention and high-frequency ranges.
Plasma concentrations of Malondialdehyde (MDA) will be measures as an indicator of oxidative stress.
Placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.